Jiskyn

Bendamustine Hydrochloride, the active ingredient in Jiskyn, is an alkylating agent presented as an injectable solution for intravenous use. It treats chronic lymphocytic leukemia and non‑Hodgkin lymphoma in adult patients.

GNH USA supplies Jiskyn as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Bendamustine Hydrochloride is used in the treatment of hematologic malignancies, particularly lymphoid cancers.

- Chronic lymphocytic leukemia (CLL): improves disease control and prolongs survival in affected patients. - Non‑Hodgkin lymphoma (NHL): induces remission and reduces tumor burden in eligible individuals.

Bendamustine Hydrochloride may cause a range of adverse reactions during therapy.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Fatigue: persistent tiredness affecting daily activities. - Neutropenia: reduced neutrophil count increasing infection risk. - Fever: low‑grade temperature elevations.

Serious or Rare Side Effects: - Severe infections: opportunistic or bacterial infections requiring medical attention. - Tumor lysis syndrome: rapid tumor breakdown causing metabolic disturbances. - Secondary malignancies: potential development of new cancers after treatment.

Before initiating therapy with Bendamustine Hydrochloride, clinicians should evaluate patient-specific factors and monitor for complications.

- Blood count monitoring: perform regular CBC to detect neutropenia or anemia. - Renal function assessment: check creatinine clearance prior to each cycle. - Hepatic function evaluation: monitor liver enzymes for potential toxicity. - Infection risk management: avoid use in patients with active severe infections. - Contraception requirement: advise both male and female patients to use effective contraception during treatment and for a defined period afterward. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Bendamustine Hydrochloride can interact with other agents, altering efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase bendamustine exposure and toxicity. - Live vaccines: concurrent use can lead to severe infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., fluconazole): may modestly raise plasma levels; monitor blood counts. - Granulocyte colony‑stimulating factors (G‑CSF): can affect neutrophil recovery; adjust dosing as needed. - Other myelosuppressive chemotherapy: combined use may exacerbate bone‑marrow suppression; schedule carefully.